|
1
|
Kolodkin AL, Matthes DJ and Goodman CS:
The semaphorin genes encode a family of transmembrane and secreted
growth cone guidance molecules. Cell. 75:1389–1399. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takahashi K, Ishida M, Hirokawa K and
Takahashi H: Expression of the semaphorins Sema 3D and Sema 3F in
the developing parathyroid and thymus. Dev Dyn. 237:1699–1708.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Behar O, Golden JA, Mashimo H, Schoen FJ
and Fishman MC: Semaphorin III is needed for normal patterning and
growth of nerves, bones and heart. Nature. 383:525–528. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gitler AD, Lu MM and Epstein JA: PlexinD1
and semaphorin signaling are required in endothelial cells for
cardiovascular development. Dev Cell. 7:107–116. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gu C, Rodriguez ER, Reimert DV, Shu T,
Fritzsch B, Richards LJ, Kolodkin AL and Ginty DD: Neuropilin-1
conveys semaphorin and VEGF signaling during neural and
cardiovascular development. Dev Cell. 5:45–57. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suzuki K, Kumanogoh A and Kikutani H:
Semaphorins and their receptors in immune cell interactions. Nat
Immunol. 9:17–23. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tse C, Xiang RH, Bracht T and Naylor SL:
Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3
suppresses tumor formation in an adenocarcinoma cell line. Cancer
Res. 62:542–546. 2002.PubMed/NCBI
|
|
8
|
Tomizawa Y, Sekido Y, Kondo M, Gao B,
Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF and Minna JD:
Inhibition of lung cancer cell growth and induction of apoptosis
after reexpression of 3p21.3 candidate tumor suppressor gene
SEMA3B. Proc Natl Acad Sci USA. 98:13954–13959. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miao HQ, Soker S, Feiner L, Alonso JL,
Raper JA and Klagsbrun M: Neuropilin-1 mediates
collapsin-1/semaphorin III inhibition of endothelial cell motility:
Functional competition of collapsin-1 and vascular endothelial
growth factor-165. J Cell Biol. 146:233–342. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kigel B, Varshavsky A, Kessler O and
Neufeld G: Successful inhibition of tumor development by specific
class-3 semaphorins is associated with expression of appropriate
semaphorin receptors by tumor cells. PLoS One. 3:e32872008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Banu N, Teichman J, Dunlap-Brown M,
Villegas G and Tufro A: Semaphorin 3C regulates endothelial cell
function by increasing integrin activity. FASEB J. 20:2150–2152.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Basile JR, Castilho RM, Williams VP and
Gutkind JS: Semaphorin 4D provides a link between axon guidance
processes and tumor-induced angiogenesis. Proc Natl Acad Sci USA.
103:9017–9022. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao XY, Chen L, Xu Q and Li YH:
Expression of semaphorin 6D in gastric carcinoma and its
significance. World Gastroenterol. 12:7388–7390. 2006. View Article : Google Scholar
|
|
14
|
O'Connor BP, Eun SY, Ye Z, Zozulya AL,
Lich JD, Moore CB, Iocca HA, Roney KE, Holl EK, Wu QP, et al:
Semaphorin 6D regulates the late phase of CD4+ T cell primary
immune responses. Proc Natl Acad Sci USA. 105:13015–13020. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Toyofuku T, Zhang H, Kumanogoh A,
Takegahara N, Suto F, Kamei J, Aoki K, Yabuki M, Hori M, Fujisawa H
and Kikutani H: Dual roles of Sema6D in cardiac morphogenesis
through region-specific association of its receptor, Plexin-A1,
with off-track and vascular endothelial growth factor receptor type
2. Genes Dev. 18:435–447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moriarity BS, Otto GM, Rahrmann EP, Rathe
SK, Wolf NK, Weg MT, Manlove LA, LaRue RS, Temiz NA, Molyneux SD,
et al: A Sleeping Beauty forward genetic screen identifies new
genes and pathways driving osteosarcoma development and metastasis.
Nat Genet. 47:615–624. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Toyofuku T, Zhang H, Kumanogoh A,
Takegahara N, Yabuki M, Harada K, Hori M and Kikutani H: Guidance
of myocardial patterning in cardiac development by Sema6D reverse
signalling. Nat Cell Biol. 6:1204–1211. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kigel B, Rabinowicz N, Varshavsky A,
Kessler O and Neufeld G: Plexin-A4 promotes tumor progression and
tumor angiogenesis by enhancement of VEGF and bFGF signaling.
Blood. 118:4285–4296. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao XY, Chen L, Li YH and Xu Q: PlexinA1
expression in gastric carcinoma and its relationship with tumor
angiogenesis and proliferation. World J Gastroenterol.
13:6558–6561. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Catalano A, Lazzarini R, Di Nuzzo S,
Orciari S and Procopio A: The plexin-A1 receptor activates vascular
endothelial growth factor-receptor 2 and nuclear factor-kappaB to
mediate survival and anchorage-independent growth of malignant
mesothelioma cells. Cancer Res. 69:1485–1493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suzuki K, Kumanogoh A and Kikutani H:
Semaphorins and their receptors in immune cell interactions. Nat
Immunol. 9:17–23. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujii T, Nakao F, Shibata Y, Shioi G,
Kodama E, Fujisawa H and Takagi S: Caenorhabditis elegans PlexinA,
PLX-1, interacts with transmembrane semaphorins and regulates
epidermal morphogenesis. Development. 129:2053–2063.
2002.PubMed/NCBI
|
|
24
|
Herzog Y, Kalcheim C, Kahane N, Reshef R
and Neufeld G: Differential expression of neuropilin-1 and
neuropilin-2 in arteries and veins. Mech Dev. 109:115–119. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ellis LM: The role of neuropilins in
cancer. Mol Cancer Ther. 5:1099–1107. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Peplow PV: Influence of growth factors and
cytokines on angiogenic function of endothelial progenitor cells: A
review of in vitro human studies. Growth Factors. 32:83–116. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meunier-Carpentier S, Dales JP, Djemli A,
Garcia S, Bonnier P, Andrac-Meyer L, Lavaut MN, Allasia C and
Charpin C: Comparison of the prognosis indication of VEGFR-1 and
VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J
Oncol. 26:977–984. 2005.PubMed/NCBI
|
|
28
|
Rahimi N: VEGFR-1 and VEGFR-2: Two
non-identical twins with a unique physiognomy. Front Biosci.
11:818–829. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang ZL, Liu ZS and Sun Q: Effects of
thalidomide on angiogenesis and tumor growth and metastasis of
human hepatocellular carcinoma in nude mice. World J Gastroenterol.
11:216–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bertolini F, Marighetti P, Martin-Padura
I, Mancuso P, Hu-Lowe DD, Shaked Y and D'Onofrio A: Anti-VEGF and
beyond: Shaping a new generation of anti-angiogenic therapies for
cancer. Drug Discov Today. 16:1052–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
